Solid Fiscal Year 2025 Performance
Siemens Healthineers closed fiscal year 2025 successfully with growth at the upper end of the outlook range and a book-to-bill ratio of 1.14. Adjusted EPS was within the upper half of the outlook, and free cash flow improved leverage to 2.8x EBITDA.
Strong Segment Growth
Imaging, Varian, and Advanced Therapies collectively increased revenue by almost 8%. Varian has grown every year by at least high single-digit percentages, and Advanced Therapies contributed solid growth by maintaining stable margins.
Diagnostics Profitability Improvement
Despite market challenges in China, the Diagnostics segment achieved a step change in profitability due to a successful transformation program.
Healthy Global Demand
Excluding China, Siemens Healthineers experienced revenue growth across all regions, with excellent performance in the Americas and EMEA.